The significance of immunohistochemistry in the diagnosis and therapy of neoplasms

Expert Opinion on Biological Therapy

Volumn 2, Issue 4, 2002, Pages 371-393

  Bodey, Bela ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cellular immunophenotype; EGF; Epidermal growth factor; Epidermal growth factor receptor; Histopathology; Immunocytochemistry; Library of poly and monoclonal antibodies; Molecular biology; Neoplasm related neoangiogenesis

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INVASION; CARCINOGENESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; METASTASIS; NEOPLASM; NONHUMAN; REVIEW; TARGET CELL;

ANIMALS; APOPTOSIS; EPIDERMAL GROWTH FACTOR; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0036249155     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.4.371     Document Type: Review

References (402)

1. Pathology of small-cell lung cancer
2. Diagnostic immunohistochemistry of tumors of the central nervous system
3. Quality assurance and standardization in immunohistochemistry. A proposal for the annual meeting of the Biological Stain Commission, June, 1991
4. Histopathologic and immunohistochemical prognostic factors in malignant gliomas
5. Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: Identification of astrocytoma subsets
6. Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids
7. Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors
8. Immunophenotypical analysis and immunobiology of childhood brain tumors
9. Immunophenotypical (IP) differential diagnosis and immunobiology of childhood primary brain tumors. A decade of experience
10. Immunocytochemical observation of multidrug resistance (MDR-p170) glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression
11. Diagnosis and clinical significance of disseminated tumor cells in bone marrow
12. Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas
13. The clinical significance of micrometastases and molecular metastases
14. Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer
15. Tumor suppressor genes
16. T-antigen is bound to host protein in SV40-transformed cells
17. Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kD cellular protein in transformed cells
18. Association of human papillomavirus types 16 and 18 E6 proteins with p53
19. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies
20. TP53 tumor suppressor gene: A model for investigating human mutagenesis
21. Mutations in the p53 rumor suppressor genes: Clues to cancer etiology and molecular pathogenesis
22. p53 mutations in human cancers
23. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
24. Germ-line transmission of a mutated p53 gene in cancer-prone family with Li-Fraumeni syndrome
25. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia
26. Constitutional p53 mutations associated with brain tumors in young adults
27. Correlation of p53 immunoreactivity and sequencing in patients with glioma
28. p53 protein overexpression in astrocytic neoplasms
29. Prognostic indicators in a range of astrocytic tumours: An immunohistochemical study with Ki-67 and p53 antibodies
30. p53 protein and epidermal growth factor receptor expression in human astrocytomas
31. p53 in cutaneous melanoma: Immunoreactivity and correlation with prognosis
32. Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions
33. Prognostic significance of p53 over-expression in thin melanomas
34. Mutation and expression of TP53 in malignant melanomas
35. p53: A frequent target for genetic abnormalities in lung cancer
36. p53 mutations in human lung tumors
37. p53 and ras gene mutations in lung cancer: Implications for smoking and occupational exposures
38. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer
39. p53 in squamous metaplasia: A marker for risk of respiratory tract carcinoma
40. The dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients
41. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines
42. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma
43. Ozturkm: p53 mutation in hepatocellular carcinoma after aflatoxin exposure
44. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with rumor growth and invasiveness
45. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma
46. p53 polymorphism in ovarian and breast cancer
47. p53 protein as a prognostic indicator in breast carcinoma: A comparison of four antibodies for immunohistochemistry
48. p53 mutations, another breast cancer prognostic factor
49. p53 expression in human breast cancer
50. The role of Tp53 in breast cancer development
51. The p53 tumor suppressor gene in breast cancer
52. p53 gene alterations in special types of breast carcinoma: A molecular and immunohistochemical study in archival material
53. Tumor suppressor p53 mutations and breast cancer: A critical analysis
54. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value
55. Mutations in the p53 gene occur in diverse human tumour types
56. p53, guardian of the genome
57. Identification of p53 as a sequence-specific DNA-binding protein
58. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication
59. New link found between p53 and DNA repair
60. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2
61. The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase II
62. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor suppressor gene isolated from nasopharyngeal carcinoma
63. ImmunocytochemicaI detection of p53 protein overexpression in primary human osteosarcomas
64. Tumor suppressor genes in childhood malignancies. A review
65. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary turnouts: Molecular and immunohistochemical findings
66. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma
67. Base transitions are the most frequent genetic changes at p53 in gastric cancer
68. Increased expression of mutant forms of p53 oncogene in primary lung cancer
69. Biochemical properties of Ha-fas encoded p21 mutants and mechanism of the autophosphorylation
70. Sequence specificity of mutations induced by benzo [a] pyrene-7,8-diol-9,10-ep oxide at endogenous aprt gene in CHO cells
71. Mutant p53 proteins bind hsp 72.73 cellular heat shock-related proteins in SV40-transformed monkey cells
72. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life
73. The role of hPMS1 and hPMS2 in predisposing to colorectal cancer
74. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system
75. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression
76. Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) patients: Mutations or polymorphisms?
77. Mutational analysis of promoters of mismatch repair genes hMSH2 and hMLH1 in hereditary nonpolyposis colorectal cancer and early onset colorectal cancer patients: Identification of three novel germ-line mutations in promoter of the hMSH2 gene
78. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas
79. DNA mismatch repair enzyme activity and gene expression in prostate cancer
80. Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association
81. Prognostic relevance of hMLH1, hMSH2, and BAX protein expression in endometrial carcinoma
82. DNA mismatch repair genes hMLH1, hMSH2, and hMSH6 are not inactivated in bronchioloalveolar carcinomas of the lung
83. hMLH1 and hMSH2 expression in human hepatocellular carcinoma
84. Angiogenesis as a target for tumor treatment
85. Angiogenesis in cancer, vascular, rheumatoid, and other disease
86. Angiogenesis: Models and modulators
87. Differentiation of endothelium
88. Vasculogenesis
89. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
90. Mechanisms and therapeutic implications of angiogenesis
91. Addressing tumor blood vessels
92. Angiogenesis and angiogenesis inhibition: An overview
93. Expression and distribution of vascular endothelial growth factor protein in human brain tumors
94. The biochemistry of cancer dissemination
95. Vascular endothelial growth factor in squamous cell head and neck carcinoma: Expression and prognostic significance
96. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
97. Angiogenic factors
98. Vascular permeability factor, an endothelial cell mitogen related to PDGF
99. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
100. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
101. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells
102. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
103. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors
104. What, if anything, is an angiogenic factor?
105. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer
106. bFGF and tumor angiogenesis - Back in the limelight?
107. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
108. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: Correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia
109. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis
110. Met and hepatocyte growth factor/scatter factor expression in human gliomas
111. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer
112. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence ofangiogenesis suppression
113. Exptession of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies
114. Role of angiogenesis inhibitors in acute myeloid leukemia
115. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas
116. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma
117. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients
118. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors
119. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms
120. Expression of vascular endothelial growth factor in capillary hemangioblastoma
121. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas
122. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients
123. Embryonic angiogenesis factors
124. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiauon
125. Molecular biology of blood-brain barrier ontogenesis and function
126. Angiogenic growth factors in neural embryogenesis and neoplasia
127. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms
128. Angiogenesis: A mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis
129. Expression of bFGF and VEGF in brain astrocyroma
130. Immunocytochemical localization of basic fibroblast growth factor in squamous cell carcinomas of the head and neck
131. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth
132. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1
133. Angiogenesis in pancreatic carcinoma: Thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival
134. Effect of scatter factor on motility of epithelial cells and fibroblasts
135. Scatter factor and other regulators of cell mobility
136. Regulation of cell movement: The motogenic cytokines
137. Immunolocalization of granulocyte-colony-stimulating factor in human glial and primitive neuroectodermal tumors
138. Hepatocyte growth factor: Clinical implications in hepatobiliary pancreatic surgery
139. Stromal involvement in malignant growth
140. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis
141. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
142. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
143. Epidermal growth factor
144. Isolation and structure of urogastrone and its relationship to epidermal growth factor
145. Signal transduction by receptors with tyrosine kinase activity
146. Lemoinenr: The Type I (EGFR-related) family of growth factor receptors and their ligands
147. Ligand-specific activation of HER-4/p180erbB4, a fourth member of the epidermal growth factor receptor family
148. Heregulin induces tyrosine phosphorylation of HER-4/p180erbB-4
149. High expression of the EGFR in fibroadenomas compared to breast carcinomas
150. Biologic and clinical significance of HER-2/neu (c-erbB-2) in breast cancer
151. Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences
152. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
153. Response to epidermal growth factor of cultured human mammary epirhehal cells from benign tumours
154. Ductal morphogenesis in the mouse mammary gland: Evidence supporting a role for epidermal growth factor
155. Growth factor expression in breast tissue
156. Transforming growth factor beta
157. Detection of transforming growth factor beta in normal, malignant, and hyperproliferative human keratinocytes
158. Overexpression of transforming growth factor beta in psoriatic epidermis
159. A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines
160. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes
161. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues
162. The neu (cerbB-2) oncogene
163. Direct interaction of a ligand for erbB2 oncogene product with the EGF receptor and p185erbB2
164. Serial serum c-erbB-2 levels in patients with breast carcinoma
165. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies
166. Requirement for neuregulin receptor erbB2 in neural and cardiac development
167. Isolation of the neu/HER-2 stimulatory ligand: A 44 kD glycoprotein that induces differentiation of mammary tumor cells
168. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit
169. Identification of heregulin, a specific activator of p 185erbB2
170. Aria, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family
171. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system
172. The erbb3 gene product is a receptor for heregulin
173. Structure-function relationships for the EGF/TGF-beta family of mitogens
174. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors
175. Epidermal growth factor in the developing mammal
176. Differentiation and proliferation patterns in human trophoblast revealed by c-erbB-2 oncogene product and EGF-R
177. Differential expression of ARIA isoforms in the rat brain
178. Multiple essential functions of neuregulin in development
179. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
180. Epidermal growth factor promotes a neural phenotype in thymic epithelial cells and enhances neuropoietic cytokine expression
181. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
182. Immunohistochemical detection of c-erbB-2 expression by neoplastic human tissue using monospecific and bispecific monoclonal antibodies
183. Growth of human gastric carcinomas and expression of epidermal growth factor, transforming growth factor-beta, epidermal growth factor receptor and pl85c-erbB-2
184. Thymoma: Tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erbB and ras p21
185. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
186. Alterations to either c-erbB2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
187. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma
188. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma
189. Expression of epidermal growth factor receptor in benign and malignant primary tumors of the breast
190. c-erbB2 mRNA expression in human breast tumours: Comparison with c-erbB2 DNA amplification and correlation with prognosis
191. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation
192. Comparison of EGF-R, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer
193. HER2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
194. Prognostic importance of c-erbB2 expression in breast cancer
195. Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study
196. The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: A review on 5232 patients
197. Epidermal growth factor receptor in breast cancer. Comparison with nonmalignant breast tissue
198. Expression of the c-erbB-2 gene product as detected in cytologic aspirates in breast cancer
199. neu(c-erbb-2/her2) and the epidermal growth factor receptor (EGFR) in breast cancer
200. Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction
201. Cooperative signaling of ErbB-3 and ErbB-2 in neoplastic transformation and human mammary carcinoma cells
202. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers
203. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer
204. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer
205. c-erbB-3 protein expression in human breast cancer: Comparison with other tumour variables and survival
206. Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma
207. c-erbB-3 protein expression in ovarian tumours
208. Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms
209. A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma
210. Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome
211. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy
212. Human transforming growth factor. Production by melanoma cell line, purification, and initial characterization
213. Ectopic peptides released by a human melanoma cell line that modulate the transformed phenotype
214. Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells
215. Biology of tumor progression in human melanocytes
216. Increased epidermal growth factor receptors in seborrheic keratoses and acrochordons of patients with dysplastic nevus syndrome
217. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas
218. The significance of oncogene amplification in primary breast cancer
219. Biomarkers in early breast neoplasia
220. c-erbB-2 amplification in mammary carcinoma
221. Breast cancer heterogeneity: Evaluation of clonality in primary and metastatic lesions
222. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs)
223. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
224. Amplification of the c-erbB-2 gene in gastric carcinoma: Correlation with survival
225. c-erbB-2 (HER2/neu) oncopeptide immunoreactivityin localized, high grade transitional cell carcinoma of the bladder
226. Expression of the c-erbB-2 (HER2/neu) oncoprotein in human prostatic cardnoma
227. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis
228. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
229. HER-2/neu expression: A major prognostic factor in endometrial cancer
230. Expression of p53, transforming growth factor beta, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival
231. HER2-neu, p53, and DNA analyses as prognostic factors for survival in endometrial carcinoma
232. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival
233. c-erbB-2 amplification in node-negative breast cancer
234. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer
235. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
236. erbb-2 amplification in breast cancer with a high rate of proliferation
237. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
238. Association of c-erbB-2 oncogene overexpression with high rate of cell proliferation, increased risk for visceral metastasis and poor long-term survival in breast cancer
239. c-erbB-2 oncoprotein expression in primary and advanced breast cancer
240. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
241. Correlation between c-erbB-2 amplification and risk of early relapse in node-negative breast cancer
242. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors
243. The long term prognostic significance of c-erbB-2 in primary breast cancer
244. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer
245. HER-2/neu expression in node-negative breast cancers: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
246. Immunohistochemical overexpression of c-erbB-2 in the prognosis of breast cancer
247. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer
248. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
249. Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions
250. Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer
251. Erbb-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer
252. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma
253. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
254. c-erbB-2 expression in benign and malignant breast disease
255. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
256. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease
257. HER-2 oncogene amplification and overall survival of breast carcinoma patients
258. c-erbB-2 protein expression in node negative breast cancer
259. Follow-up study of HER-2/neu amplification in primary breast cancer
260. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
261. Expression of erbB3 gene product in breast cancer
262. Production and characterisation of a polyclonal antibody to the c-erbB3 protein: Examination of c-erbB3 protein expression in adenocarcinomas
263. Expression of the c-erbB3 gene product in gastric cancer
264. Expression of the c-erbB3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1
265. The erbB3 gene in human pancreatic cancer
266. Trace elements and apoptosis
267. To die or not to die: An overview of apoptosis and its role in disease
268. Cell deaths in normal vertebrate ontogeny
269. Death in embryonic systems
270. Patterns of cell death
271. Premature p34cdc2 activation required for apoptosis
272. Cell cycle and apoptosis: Common pathways to life and death
273. Apoptosis and the cell cycle
274. Activation of cyclin E-dependent kinase by DNA-damage signals during apoptosis
275. Life, death, and the pursuit of apoptosis
276. Control of programmed cell death in normal and leukemic cells: New implication for therapy
277. Regulation of apoptosis in immune cells
278. Defining apoptosis
279. Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome
280. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
281. Apoptosis: Mechanisms and roles in pathology
282. The role of proteases during apoptosis
283. Dicing with death: Dissecting the components of the apoptosis machinery
284. The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium
285. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
286. Cell death: The significance of apoptosis
287. Hormone-induced cell death. 2. Surface changes in thymocytes undergoing apoptosis
288. Apoptosis: The role of the endonuclease
289. Apoptosis and cancer
290. Endogenous endonuclease induced DNA fragmentation: An early event in cell mediated cytolysis
291. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death
292. Phagocyte recognition of cells undergoing apoptosis
293. Apoptosis and Bcl-2 oncoprotein expression in the human fetal central nervous system
294. Monoclonal antibody-mediated tumor regression by induction of apoptosis
295. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
296. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas
297. Induction of apoptosis in fibroblasts by c-myc protein
298. Bcl-2: A repressor of lymphocyte death
299. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation
300. Molecular controls of apoptosis: Differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators
301. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo
302. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
303. Cloning of mouse Ox40: A T cell activation marker that may mediate T-B cell interactions
304. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
305. Fas and Fas ligand: A death factor and its receptor
306. Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody
307. Fas (APO-1, CD95) receptor expression and new options of immunotherapy in childhood medulloblastomas
308. Fas (APO-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
309. Fas transduces activation signals in normal human T lymphocytes
310. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
311. Lethal effect of the anti-Fas antibody in mice
312. Molecular cloning and expression of the Fas ligand: A novel member of the tumor necrosis factor family
313. Purification and characterization of the Fas ligand that induces apoptosis
314. The Fas death factor
315. The Fas/apo-1 receptor and its deadly ligand
316. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease
317. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
318. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
319. Abnormal thymocyte development and production of autoreactive T cells in TCR transgenic autoimmune mice
320. Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mouse
321. Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse
322. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement
323. Activation interferes with the APO-1 pathway in mature human T cells
324. Dephosphorylation of a 65kD protein associated with signaling for Fas-mediated apoptosis
325. c-Myc and apoptosis
326. Thymocyte apoptosis induced by p53-dependent and independent pathways
327. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2
328. Expression of p53 related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders
329. Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in rumor progression
330. Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance
331. p53-dependent DNA damage-induced apoptosis requires. Fas-APO-1-independent activation of CPP321
332. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
333. Bcl-2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells
334. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
335. Bcl-2 is the guardian of microtubule integrity
336. Bcl-2 heterodimerizes in vivo with a conserved homolog Bax that accelerates programmed cell death
337. Spontaneous programmed cell death in infiltrating duct carcinoma: Association with p53, BCL-2, hormone receptors and tumor proliferation
338. The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death
339. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death
340. Mechanisms and genes of cellular suicide
341. Bcl-2 and the regulation of programmed cell death
342. The overexpression of bcl-2 inhibits UVA-mediated immediate apoptosis in rat 6 fibroblasts: Evidence for the involvement of bcl-2 as an antioxidant
343. Human ICE/CED-3 protease nomenclature
344. Induction of apoptosis by the mouse Nedd 2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1beta- converting enzyme
345. Malignant lymphoma arising from natural killer cells: Report of the first case in 1970 and newer developments in the FasL → FasR system
346. Ich-1, an Ice/ced-3 related gene, encodes both positive and negative regulators of programmed cell death
347. Identification and characterization of ICH-2, a novel member of the interleukin-1beta-converting enzyme family of cysteine proteases
348. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1beta-converting enzyme
349. Mch2, a new member of the apoptotic Ced-3/ICE cysteine protease gene family
350. Molecular cloning and proapoptotic activity of ICErelII and ICErelIII members of the ICE/Ced-3 family of cysteine proteases
351. ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis
352. ICE-LAP6, a novel member of the ICE-Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B
353. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death
354. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
355. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
356. Apoptosis or planning a death
357. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells
358. Participation of p53 in the cellular response to DNA damage
359. Relationship between radiation-induced G1 phase arrest and p53 in human tumor cells
360. p53 mutations increase resistance to ionizing radiation
361. p53 is required for radiation-induced apoptosis in mouse thymocytes
362. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
363. Disruption of p53 sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline
364. Chemotherapy and Herceptin for HER-2+ metastatic breast cancer: The best drug?
365. The HER-2/neu oncogene in tumors of the gastrointestinal tract
366. Tumor therapy with targeted atomic nanogenerators
367. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer
368. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors
369. The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis
370. Tumor angiogenesis: Therapeutic implications
371. Clinical applications of research on angiogenesis
372. The implications ofangiogenesis for the biology and therapy of cancer metastasis
373. Tumour angiogenesis
374. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool
375. Combretasratin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
376. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
377. Function and regulation of ras
378. Phosphatidyhnositol-3-OH kinase as a direct target of Ras
379. Signaling, mirogenesis and the cytoskeleton: Where the action is
380. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase
381. Binding of NCK to SOS and activation of ras-dependent gene expression
382. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
383. Fighting cancer by attacking its blood supply
384. New perspectives in clinical oncology from angiogenesis research
385. Thalidomide is an inhibitor of angiogenesis
386. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, proliferation, and induction of urokinase-type plasminogen activator
387. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo
388. Selective inhibition of adhesion molecule expression by edelfosine (ET-18-OCH3) on human umbilical vein or microvascular endothelium
389. Inhibition of angiogenesis in vivo by interleukin- 12
390. Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential
391. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11
392. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo
393. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
394. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol
395. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer
396. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells
397. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
398. Oncogenes as inducers of tumor angiogenesis
399. Gene therapy of malignant glioma via inhibition of tumor angiogenesis
400. Comparative aspects of neoplastic invasion of the brain
401. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer